Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study.
Ahmad AlbsheshJoshua TaylorEdoardo V SavarinoMarie TruyensAlessandro ArmuzziDavide Giuseppe RibaldoneAriella Bar-Gil ShitritMorine FibelmanPauliina MolanderClaire LiefferinckxStephane NanceyMohamed KoraniMariann RutkaManuel Barreiro-De-AcostaViktor DomislovicGerard SurisCarl ErikssonCatarina AlvesAfroditi MpitouliCaroline di JiangKatja TepešMarina ColettaKalliopi FoteinogiannopoulouFrancisco Javier García-AlonsoHadar Amir-BarakMohamed AttauabiJakob SeidelinWaqqas AfifCarla MarinelliTriana LobatonDaniela PuglieseNitsan MaharshakAnneline CremerJimmy K LimdiTamás MolnárBorja Otero-AlvarinŽeljko KrznarićFernando MagroKonstantinos KarmirisTim RaineDavid DrobneIoannis KoutroubakisMaria ChaparroHenit YanaiBurisch JUri KopylovPublished in: Journal of clinical medicine (2021)
Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.